Last reviewed · How we verify
Edoxaban Treatment in Routine Clinical Practice for Patients With Atrial Fibrillation in Korea and Taiwan (ETNA-AF-KOR-TWN)
In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the Non valvular Atrial Fibrillation (NVAF) indication, Daiichi-Sankyo proposed this non-interventional study to gain insight into the safety (bleeding, liver adverse events, all-cause mortality and other drug related adverse events) and efficacy of edoxaban use in non-preselected patients with NVAF.
Details
| Lead sponsor | Daiichi Sankyo |
|---|---|
| Status | COMPLETED |
| Enrolment | 3008 |
| Start date | Tue Feb 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Oct 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Atrial Fibrillation
Interventions
- Edoxaban
Countries
Taiwan, South Korea